Hq Spclt Pharma Company Profile
What is the competitive landscape for HQ SPCLT PHARMA
HQ SPCLT PHARMA has fifteen approved drugs.
There are six US patents protecting HQ SPCLT PHARMA drugs.
Summary for Hq Spclt Pharma
| US Patents: | 6 |
| Tradenames: | 18 |
| Ingredients: | 12 |
| NDAs: | 15 |
Drugs and US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | CALCIUM GLUCONATE IN SODIUM CHLORIDE | calcium gluconate | SOLUTION;INTRAVENOUS | 210906-003 | Jun 4, 2021 | RX | Yes | Yes | 10,130,646 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hq Spclt Pharma | CEFAZOLIN SODIUM | cefazolin sodium | POWDER;INTRAVENOUS | 211413-001 | May 8, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Hq Spclt Pharma | MAGNESIUM SULFATE IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 207350-002 | Dec 6, 2017 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hq Spclt Pharma | LEVETIRACETAM IN SODIUM CHLORIDE | levetiracetam | INJECTABLE;INTRAVENOUS | 202543-003 | Nov 9, 2011 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 5,562,925 | ⤷ Start Trial |
| Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-002 | Approved Prior to Jan 1, 1982 | 4,177,263 | ⤷ Start Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,177,263 | ⤷ Start Trial |
| Hq Spclt Pharma | TAXOL | paclitaxel | INJECTABLE;INJECTION | 020262-001 | Dec 29, 1992 | 5,496,804 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hq Spclt Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20150132835 | ⤷ Start Trial |
| Argentina | 108806 | ⤷ Start Trial |
| South Africa | 201807466 | ⤷ Start Trial |
| China | 105263809 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hq Spclt Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2957286 | 300962 | Netherlands | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170721 |
| 2666774 | SPC/GB20/031 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: RELEBACTAM OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT.; REGISTERED: UK EU/1/19/1420 (NI) 20200217; UK PLGB 53095/0053 20200217 |
| 0717738 | PA2004004,C0717738 | Lithuania | ⤷ Start Trial | PRODUCT NAME: LINEZOLIDUM ((S)-N-((3-(3-FLUOR-4-(4-MORFOLINIL)FENIL)-2-OKSO--5-OKSAZOLIDINIL)METIL)-ACETAMIDAS); REGISTRATION NO/DATE: 02/8199/2 20030313 |
| 1499331 | 13C0055 | France | ⤷ Start Trial | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
